Papillary Thyroid Cancer Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017

November 2017 | 72 pages | ID: P318BDB6AB8EN
VPAResearch

Abstracts

Thyroid Cancer is the cancer type originating in Thyroid gland. Though specific causes are not determined, the cancer occurs when thyroid cells undergo mutations, making cells to increase rapidly in count and size, forming tumors.

Types-

Thyroid Cancer is categorized into three main types –

• Differentiated Thyroid Cancer
• Follicular
• Papillary
• Hurthle
• Medullary Thyroid Cancer
• Sporadic
• Familial
• Anaplastic Thyroid Cancer

Stages-

• Stage I - Tumor less than 2 cm
• Stage II - Tumor between 2 cm and 4 cm
• Stage III - Tumor more than 4 cm, or grown slightly beyond thyroid
• Stage IVa- Tumor expands into nearby neck tissues/ some lymph nodes/ upper chest
• Stage IVb- Tumor expands to spine/ blood vessels
• Stage IVC: Tumor might be spread to distant sites of body

Companies conducting Papillary Thyroid Cancer trials include-

• Ignyta, Inc.
• Hoffmann-La Roche
• Exelixis
• Genzyme Europe B.V.

Papillary Thyroid Cancer clinical trials report from VPA Research provides comprehensive analysis and trends in global Papillary Thyroid Cancer disease clinical trials. The research work analyzes the evolution of Papillary Thyroid Cancer clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Papillary Thyroid Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Papillary Thyroid Cancer clinical trials.

Major drugs under development in Papillary Thyroid Cancer are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.

Scope of the Report-

• Number of Papillary Thyroid Cancer clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
• Trial information by Phase and Subjects recruited
• Trial information by status, type, sponsor type
• Drugs used for treatment of Papillary Thyroid Cancer
• Both observational and interventional trials analyzed
• Success rates of trials are analyzed
• Trends in enrollment over the past ten years identified
• Leading sponsors of Papillary Thyroid Cancer clinical trials worldwide are listed

Reasons to Buy-

• Track competition and design competitive advantages
• Identify right partners to associate with for further research
• Evaluate potential opportunities available in further clinical trials of the disease
• Formulate business development strategies through success rates of clinical trials
• Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

1.1 LIST OF FIGURES
1.2 LIST OF TABLES

2 EXECUTIVE SUMMARY

2.1 Report Guide
2.2 Key Findings
  2.2.1 Overview of Global Clinical Trials Conducted in 2017
  2.2.2 Average Enrolment by Country, 2010- 2017
  2.2.3 Prominent Companies in Global Papillary Thyroid Cancer Trials, 2010- 2017
  2.2.4 Inverse Relation between TSH levels and Thyroid Cancer Observed
  2.2.5 Primary users with regular Thyroxine found to have increased risk of Thyroid Cancer
  2.2.6 Radioactive Iodine use as follow-up treatment for Thyroid Cancer to Increase AML risk

3 PAPILLARY THYROID CANCER DRUGS IN ONGOING AND COMPLETED TRIALS

3.1 Prominent Drugs in Development and Approved Stages for Papillary Thyroid Cancer
3.2 Papillary Thyroid Cancer Product Snapshots
  3.2.1 Papillary Thyroid Cancer Drug Profiles

4 GLOBAL PAPILLARY THYROID CANCER CLINICAL TRIAL RESEARCH TRENDS

4.1 Clinical Trials by Top 10 Countries, 2010- 2017
  4.1.1 Clinical Trials by Country
  4.1.2 Number of Ongoing Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010- 2017
  4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010- 2017
4.4 Subjects Recruited by Region, 2010- 2017
4.5 Clinical Trials by Year, 2010- 2017
4.6 Subjects Recruited by Year, 2010- 2017
4.7 Clinical Trials by Development Phase, 2010- 2017
  4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010- 2017
4.9 Clinical Trials by Status, 2010- 2017
4.10 Subjects Recruited by Trial Status, 2010- 2017
4.11 Clinical Trials by Sponsor Type, 2010- 2017
4.12 Subjects Recruited by Sponsor Type, 2010- 2017
4.13 Clinical Trials by Economy Type, 2010- 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010- 2017

5 EUROPE PAPILLARY THYROID CANCER CLINICAL TRIAL RESEARCH TRENDS

5.1 Clinical Trials by Top Countries in Europe, 2010- 2017
  5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010- 2017
  5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010- 2017
5.4 Europe, Clinical Trials by Development Phase, 2010- 2017
5.5 Europe, Clinical Trials by Trial Status, 2010- 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010- 2017

6 NORTH AMERICA PAPILLARY THYROID CANCER CLINICAL TRIAL RESEARCH TRENDS

6.1 Clinical Trials by Top Countries in North America, 2010- 2017
  6.1.1 North America, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in North America, 2010- 2017
  6.2.1 North America, Total Enrolment by Country
6.3 North America, Clinical Trials by Year, 2010- 2017
6.4 North America, Clinical Trials by Development Phase, 2010- 2017
6.5 North America, Clinical Trials by Trial Status, 2010- 2017
6.6 North America, Clinical Trials by Sponsor Type, 2010- 2017

7 WESTERN PACIFIC PAPILLARY THYROID CANCER CLINICAL TRIAL RESEARCH TRENDS

7.1 Clinical Trials by Top Countries in Western Pacific, 2010- 2017
  7.1.1 Western Pacific, Clinical Trials by Country
7.2 Subjects Recruited by Top Countries in Western Pacific, 2010- 2017
  7.2.1 Western Pacific, Total Enrolment by Country
7.3 Western Pacific, Clinical Trials by Year, 2010- 2017
7.4 Western Pacific, Clinical Trials by Development Phase, 2010- 2017
7.5 Western Pacific, Clinical Trials by Trial Status, 2010- 2017
7.6 Western Pacific, Clinical Trials by Sponsor Type, 2010- 2017

8 SOUTH AND CENTRAL AMERICA PAPILLARY THYROID CANCER CLINICAL TRIAL RESEARCH TRENDS

9 RECENT CLINICAL TRIALS- SNAPSHOTS

9.1 Papillary Thyroid Cancer Trial Snapshots- 2017
9.2 Papillary Thyroid Cancer Trial Snapshots- 2015
9.3 Papillary Thyroid Cancer Trial Snapshots- 2014
9.4 Papillary Thyroid Cancer Trial Snapshots- 2013
9.5 Papillary Thyroid Cancer Trial Snapshots- 2012
9.6 Papillary Thyroid Cancer Trial Snapshots- 2011
9.7 Papillary Thyroid Cancer Trial Snapshots- 2010

10 APPENDIX

10.1 About VPA Research
10.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Papillary Thyroid Cancer- Average Enrolment by Country, 2010- 2017
Figure 2: Papillary Thyroid Cancer- Country wise Clinical Trials, 2010- 2017
Figure 3: Papillary Thyroid Cancer- Country wise Ongoing Sites, 2010- 2017
Figure 4: Papillary Thyroid Cancer- Country wise Subjects Recruited, 2010- 2017
Figure 5: Global Papillary Thyroid Cancer Clinical Trials Participation Share by Region, 2010- 2017
Figure 6: Global Papillary Thyroid Cancer Subjects Recruited by Region, 2010- 2017
Figure 7: Global Papillary Thyroid Cancer Clinical Trials by Year, 2010- 2017
Figure 8: Global Papillary Thyroid Cancer Subjects Recruited by Year, 2010- 2017
Figure 9: Global Papillary Thyroid Cancer Trials by Phase, 2010- 2017
Figure 10: Global Papillary Thyroid Cancer- Subjects Recruited by Phase, 2010- 2017
Figure 11: Global Papillary Thyroid Cancer- Clinical Trials by Recruitment Status, 2010- 2017
Figure 12: Global Papillary Thyroid Cancer- Subjects Recruited by Trial Status, 2010- 2017
Figure 13: Global Papillary Thyroid Cancer- Clinical Trials by Sponsor Type, 2010- 2017
Figure 14: Global Papillary Thyroid Cancer- Subjects Recruited by Trial Status, 2010- 2017
Figure 15: Global Papillary Thyroid Cancer- Clinical Trials by Type of Economy, 2010- 2017
Figure 16: Europe Papillary Thyroid Cancer- Country wise Clinical Trials, 2010- 2017
Figure 17: Europe Papillary Thyroid Cancer- Country wise Subjects Recruited, 2010- 2017
Figure 18: Europe Papillary Thyroid Cancer- Year wise Clinical Trials, 2010- 2017
Figure 19: Europe Papillary Thyroid Cancer Trials by Phase, 2010- 2017
Figure 20: Europe Papillary Thyroid Cancer- Clinical Trials by Recruitment Status, 2010- 2017
Figure 21: Europe Papillary Thyroid Cancer- Clinical Trials by Sponsor Type, 2010- 2017
Figure 22: North America Papillary Thyroid Cancer- Country wise Clinical Trials, 2010- 2017
Figure 23: North America Papillary Thyroid Cancer- Country wise Subjects Recruited, 2010- 2017
Figure 24: North America Papillary Thyroid Cancer- Year wise Clinical Trials, 2010- 2017
Figure 25: North America Papillary Thyroid Cancer Trials by Phase, 2010- 2017
Figure 26: North America Papillary Thyroid Cancer- Clinical Trials by Recruitment Status, 2010- 2017
Figure 27: North America Papillary Thyroid Cancer- Clinical Trials by Sponsor Type, 2010- 2017
Figure 28: Western Pacific Papillary Thyroid Cancer- Country wise Clinical Trials, 2010- 2017
Figure 29: Western Pacific Papillary Thyroid Cancer- Country wise Subjects Recruited, 2010- 2017
Figure 30: Western Pacific Papillary Thyroid Cancer- Year wise Clinical Trials, 2010- 2017
Figure 31: Western Pacific Papillary Thyroid Cancer Trials by Phase, 2010- 2017
Figure 32: Western Pacific Papillary Thyroid Cancer- Clinical Trials by Recruitment Status, 2010- 2017
Figure 33: Western Pacific Papillary Thyroid Cancer- Clinical Trials by Sponsor Type, 2010- 2017

List Of Tables

LIST OF TABLES

Table 1: Papillary Thyroid Cancer Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (1)
Table 2: Papillary Thyroid Cancer Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (2)
Table 3: Papillary Thyroid Cancer Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (3)
Table 4: Papillary Thyroid Cancer Pipeline Drug Profiles- Type, Class, Route of Administration, Mechanism of Action, Target (4)
Table 5: Papillary Thyroid Cancer- Region wise Clinical Trials, 2010- 2017
Table 6: Papillary Thyroid Cancer- Region wise Subjects Recruited, 2010- 2017
Table 7: Global Papillary Thyroid Cancer- Clinical Trials and Subjects by Trial Type, 2010- 2017
Table 8: Papillary Thyroid Cancer Trial Snapshots- 2017
Table 9: Papillary Thyroid Cancer Trial Snapshots- 2017
Table 10: Papillary Thyroid Cancer Trial Snapshots- 2015
Table 11: Papillary Thyroid Cancer Trial Snapshots- 2015
Table 12: Papillary Thyroid Cancer Trial Snapshots- 2015
Table 13: Papillary Thyroid Cancer Trial Snapshots- 2014
Table 14: Papillary Thyroid Cancer Trial Snapshots- 2014
Table 15: Papillary Thyroid Cancer Trial Snapshots- 2013
Table 16: Papillary Thyroid Cancer Trial Snapshots- 2013
Table 17: Papillary Thyroid Cancer Trial Snapshots- 2013
Table 18: Papillary Thyroid Cancer Trial Snapshots- 2012
Table 19: Papillary Thyroid Cancer Trial Snapshots- 2012
Table 20: Papillary Thyroid Cancer Trial Snapshots- 2012
Table 21: Papillary Thyroid Cancer Trial Snapshots- 2012
Table 22: Papillary Thyroid Cancer Trial Snapshots- 2011
Table 23: Papillary Thyroid Cancer Trial Snapshots- 2011
Table 24: Papillary Thyroid Cancer Trial Snapshots- 2011
Table 25: Papillary Thyroid Cancer Trial Snapshots- 2010
Table 26: Papillary Thyroid Cancer Trial Snapshots- 2010